A Canadian biotech firm has launched a smart data platform designed to provide better personalized treatment options to cancer patients based on their genetic profile. Using a combination of artificial intelligence, virtual reality and complex mathematical algorithms, ROSALIND makes it possible to more quickly assess what treatments may be most effective for an individual’s specific cancer and identify patterns related to potential drug side effects.
The team of scientists at Critical Outcome Technologies Inc. have spent several years evaluating our collective knowledge about cell signaling pathways in normal cells and how gene mutations alter these pathways in cancer cells. The underlying principle behind ROSALIND is that any hope of sustained remission is dependent on therapies that restore normal cell signaling to regulate cell division and apoptosis.
While access to high-quality cancer gene mutation profiling continues to evolve, personalized cancer therapy has been a big data problem. For example, the number of unique single, double, and triple drug combinations from just 150 cancer drugs would be in excess of 540,000. This is simply too many potential therapies for any physician or group of physicians to evaluate. ROSALIND addresses this big data problem. The platform is driven by a dynamic, programmable computer simulation of how cell signaling pathways are altered by specific gene mutations that are associated with specific types of cancers. The resultant mutations determine new cancer cell signaling profiles and identify which pathways have been affected.
The underlying patent pending technology produces a comprehensive mathematical model of cell signaling based on established relationships between individual cell signaling proteins. The platform is designed to help oncologists explore different agents or combinations that show the best promise of restoring normal cell signaling resulting in a possible remission. At this time, only physicians can order a ROSALIND assessment.